SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms
There are 2 parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of SL-401 that can be given to patients with either myelofibrosis (MF) or chronic myelomonocytic leukemia (CMML). The goal of Part 2 of this research study is to learn if the dose found in Part 1 can help to control the disease. The safety of this drug will be studied in both parts of this study.
Disease Group: Myeloproliferative Diseases
Treatment Agent: SL-401
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Stemline Therapeutics, Inc.
IRB Review and Approval Date: 07/02/2015
Recruitment Status: Open
Projected Accrual: 96
Information and next steps
Phase I/Phase II
For general questions about clinical trials: